Dorzolamide
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Dorzolamide: From Open-Angle Glaucoma to Primary Hereditary Glaucoma
One-Sentence Summary
Dorzolamide is a topical carbonic anhydrase inhibitor eye drop. It is used to lower intraocular pressure (IOP) in open-angle glaucoma, an established use taken from the evidence pack’s rationale rather than from SAHPRA indication text. The TxGNN model predicts it may help primary hereditary glaucoma, but this is supported by only 1 Phase 2 clinical trial and no publications.
Quick Overview
| Item | Content |
|---|---|
| Predicted New Indication | Primary hereditary glaucoma |
| TxGNN Prediction Score | 99.99% |
| Evidence Level | L2 (a single completed Phase 2 trial, with limited confirmation of dorzolamide’s specific role) |
| South Africa Market Status | Marketed |
| Number of SAHPRA Registrations | 2 |
| Recommended Decision | Hold (the source pack labels this “Research Question”) |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the pack. Dorzolamide is generally understood to inhibit carbonic anhydrase II in the ciliary body. This reduces aqueous humour production and lowers IOP. That mechanism is the established basis for its use in open-angle glaucoma.
Primary hereditary glaucoma is a heterogeneous group that includes congenital forms. Lowering IOP is still a plausible way to protect the optic nerve in these conditions. However, efficacy may differ from adult open-angle disease, and topical carbonic anhydrase inhibitors need caution in paediatric patients. The mechanistic link is therefore reasonable but unproven.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT01527682 | Phase 2 | Completed (2009–2016) | 37 | Latanoprost and dorzolamide were assessed for ocular hypotensive effect and safety in paediatric glaucoma refractory to surgery. Results are not reported in the pack. |
Limitations:
- Dorzolamide was studied together with a prostaglandin analogue, so its individual contribution cannot be separated.
- The trial population is “primary paediatric glaucoma”, not confirmed as hereditary glaucoma.
- The protocol was amended, reducing the planned eyes from 96 to 68.
Literature Evidence
Currently no related literature available.
South Africa Market Information
| Registration Number | Product Name | Dosage Form |
|---|---|---|
| Reg. No. 54/15.4/0257 | Dorzopt Forte | Drops |
| Reg. No. 51/15.4/0162 | Ocudor Co | Drops |
Approved indication text is not recorded for these registrations, so it should be checked against the SAHPRA-approved Professional Information (PI).
Safety Considerations
- Paediatric use: Topical carbonic anhydrase inhibitors need caution in paediatric patients. This matters here because congenital and hereditary glaucoma mainly affect children.
Please refer to the SAHPRA-approved Professional Information (PI) for full warnings, contraindications and interactions. Report adverse drug reactions to SAHPRA.
Conclusion and Next Steps
Decision: Hold
Rationale: The only support is one small Phase 2 trial (n=37) that tested dorzolamide together with latanoprost in a broader paediatric glaucoma population. There is no supporting literature, and the paediatric safety review cannot proceed without the SAHPRA PI.
Other predictions in the same pack:
- Open-angle glaucoma (ranks 6–7): L1 evidence with many Phase 3 and 4 trials. It is an established use rather than new repurposing, and the two entries overlap and should be merged.
- Hair-loss conditions, congestive heart failure, acute pulmonary heart disease and respiratory failure: no credible mechanism or supporting evidence. All are Hold and likely reflect knowledge-graph artefacts.
To proceed, the following is needed:
- The SAHPRA package insert (warnings, contraindications, paediatric use). This is a blocking gap.
- Published results of NCT01527682, with dorzolamide’s individual effect and the hereditary-glaucoma subgroup.
- Mechanism of action data (MOA) from DrugBank.
- Confirmation of the approved indication text for both SAHPRA registrations.
This report is for research reference only and does not constitute medical advice. Predicted indications require clinical validation before use.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.